Faes Farma, S.A. Faes Farma, S.A.

Faes Farma, S.A.

FAE

Rank in Stocks #6367
Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research,... Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international markets. The company's comprehensive product line encompasses prescription drugs, generic alternatives, over-the-counter (OTC) remedies, nutritional supplements, infant formula, and various other health-related items. Among its diverse offerings are Actimag (a magnesium pidolate), the anti-allergic Bilaxten, the anti-infective Bronquidiazina CR, Claversal for ulcerative colitis and Crohn's disease, the corticoid Dezacor, the anti-inflammatory Dolotren (also available as Dolotren Gel), Dynamogen (an anti-anorexic), Ferroprotina (an anti-anaemic), Hidroferol, Lipofen, Positon for dermatological conditions, strength-enhancing products such as Potenciator and Surmenalit, the laxative Pruina, the muscle relaxant and analgesic Robaxisal Compuesto, Trausan (a citicoline-based product), the venous vasoprotector Venosmil (and Venosmil Gel), and the anti-influenza medication Yendol. Furthermore, Faes Farma provides key active pharmaceutical ingredients, including Bilastine (an antihistamine molecule for allergic rhinitis, conjunctivitis, and urticaria), Calcifediol for bone metabolism, Deflazacort for treating osteoarticular diseases, Hidrosmin for venous insufficiency, and Mesalazine for digestive problems. The firm also engages in significant export activities. Founded in 1933, Faes Farma, S.A. is headquartered in Leioa, Spain.
Share Price
$5.48
Last synced: 2026-11-18
Market Cap
$1.71B
Change (1 day)
-0.53%
Change (1 year)
3.14%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for Faes Farma, S.A. (FAE)
Operating Margin as of November 2026 TTM: 24.55%
According to Faes Farma, S.A.'s latest financial reports, its current operating margin (TTM) is 24.55%. At the end of 2025 the company had an operating margin of 11.92%.
Operating Margin history for Faes Farma, S.A. from 2003 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 24.55% 105.96%
2025 11.92% -45.04%
2024 21.69% 20.50%
2023 18.00% -0.50%
2022 18.09% 6.91%
2021 16.92% 4.90%
2020 16.13% -26.85%
2019 22.05% 15.32%
2018 19.12% 6.40%
2017 17.97% -14.39%
2016 20.99% 2.69%
2015 20.44% 8.32%
2014 18.87% 18.68%
2013 15.90% 22.50%
2012 12.98% 66.20%
2011 7.81% -32.09%
2010 11.50% 7.18%
2009 10.73% -22.75%
2008 13.89% 21.84%
2007 11.40% -6.79%
2006 12.23% -10.53%
2005 13.67% -29.13%
2004 19.29% 34.80%
2003 14.31% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
19.69% -99.20%
DE
19.68% -99.20%
DE
13.26% -99.46%
JP
17.08% -99.30%
CH
10.53% -99.57%
IL
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Faes Farma, S.A.'s operating margin

What is Faes Farma, S.A.'s operating margin?

Faes Farma, S.A.'s operating margin is 24.55%, as of Nov 2026.

What was Faes Farma, S.A.'s operating margin in 2025?

In 2025, Faes Farma, S.A.'s operating margin was 11.92%, compared with 21.69% in 2024.

How has Faes Farma, S.A.'s operating margin changed since 2020?

From 2020 to 2025, Faes Farma, S.A.'s operating margin was highest in 2024 (21.69%) and lowest in 2025 (11.92%).

How does Faes Farma, S.A.'s operating margin compare with similar companies?

Faes Farma, S.A.'s operating margin (24.55%) is higher than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with 19.69%.